Novo Nordisk 'B'

Late-stage STEP Young showed semaglutide led 40.4% of treated children to no longer be classified as having obesity after 68 weeks versus none on placebo, alongside lifestyle interventions. The result opens a potential pediatric market for Wegovy but commercial impact depends on regulatory approval, physician and parental adoption, reimbursement and timing. The program also comes as Novo faces pressure from Eli Lilly after CagriSema missed non-inferiority, and investor positioning on Novo remains mixed. » More on finance.yahoo.com

Novo Nordisk shares dropped 3.4 percent after Morgan Stanley cut the rating to "Underweight." The analyst criticized the weak medium-term growth prospects and pointed to the approaching patent expiry of semaglutide. » More on finanzen.net

Morgan Stanley cut Novo Nordisk from Equal-Weight to Underweight and kept the price target at DKK 250, saying the valuation does not reflect the muted medium‑term growth outlook. Analyst Thibault Boutherin points to the patent expiry of semaglutide in the early 2030s, which could create significant headwinds, even though the weight‑loss pill will account for much of 2026 sales. The stock fell more than 2% and broke short‑term supports; Morgan Stanley expects no new catalysts from the capital markets day on Sept. 21, so future gains are likely to depend more on larger acquisitions or mergers. » More on deraktionaer.de